Factor VIIa
Factor VIIa
Factor VIIa is the active form of factor VII and plays an important role in the process of blood coagulation. Factor VIIa can combine with tissue factor to form a complex, activating factor IX and factor X, thereby promoting blood coagulation. In addition, when there is vascular injury, factor VIIa can quickly initiate the blood coagulation process, forming a fibrin clot at the site of injury to achieve physiological hemostasis. Factor VIIa is closely related to diseases. Its deficiency can lead to excessive bleeding, and an excessively high level of it can increase the risk of thrombotic diseases. Factor VIIa, due to its well-known ability to promote coagulation, is also used as a hemostatic agent in the treatment of several hyper bleeding disorders like hemophilia, thrombocytopenia etc[1][2].
Referencias:
- [1]. Chatterjee A, et al. Beyond coagulation: Coagulation protease factor VIIa in cytoprotective response. Int Immunopharmacol. 2025 Mar 26;150:114218. [Content Brief]
- [2]. Persson E, et al. Allosteric activation of coagulation factor VIIa. Front Biosci (Landmark Ed). 2011 Jun 1;16(8):3156-63. [Content Brief]
All Product Categories
-
Productos relacionados con Factor VIIa (7)
Productos relacionados con (7)
-
ARC19499 sodium
0 ImagesReferencia número: HY-153480APureza: 99.40%Synonyms: BAX499 sodiumARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
-
BMS-593214
0 ImagesBMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT).
-
ARC19499
0 ImagesReferencia número: HY-153480No. CAS: 1350667-54-7Synonyms: BAX499ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
-
E-76
0 ImagesReferencia número: HY-P3235No. CAS: 1926163-13-4E-76 is a peptide with anticoagulant activity. E-76 inhibits blood coagulation by specifically binding to exogenous coagulation factor VIIa (FVIIa). E-76 can be used to study blood coagulation-related diseases.
-
ARC19499 sodium scrambled negative control
0 ImagesReferencia número: HY-153480CARC19499 sodium scrambled negative control is the sequence scrambled negative control of ARC19499 sodium.
-
Vatreptacog alfa
0 ImagesReferencia número: HY-P992152No. CAS: 897936-89-9Synonyms: NN-1731Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia.
